Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy
Autor
Lodigiani, Corrado
Iapichino, Giacomo
Carenzo, Luca
Cecconi, Maurizio
Ferrazzi, Paola
Sebastian, Tim
Kucher, Nils
Studt, Jan-Dirk
Sacco, Clara
Alexia, Bertuzzi
Sandri, Maria Teresa
Barco, Stefano
Institución
Resumen
Background: Few data are available on the rate and characteristics of thromboembolic complications in hospitalized patients with COVID-19.
Methods: We studied consecutive symptomatic patients with laboratory-proven COVID-19 admitted to a university hospital in Milan, Italy (13.02.2020–10.04.2020). The primary outcome was any thromboembolic
complication, including venous thromboembolism (VTE), ischemic stroke, and acute coronary syndrome (ACS)/
myocardial infarction (MI). Secondary outcome was overt disseminated intravascular coagulation (DIC).
Results: We included 388 patients (median age 66 years, 68% men, 16% requiring intensive care [ICU]).
Thromboprophylaxis was used in 100% of ICU patients and 75% of those on the general ward. Thromboembolic
events occurred in 28 (7.7% of closed cases; 95%CI 5.4%–11.0%), corresponding to a cumulative rate of 21%
(27.6% ICU, 6.6% general ward). Half of the thromboembolic events were diagnosed within 24 h of hospital
admission. Forty-four patients underwent VTE imaging tests and VTE was confirmed in 16 (36%). Computed
tomography pulmonary angiography (CTPA) was performed in 30 patients, corresponding to 7.7% of total, and
pulmonary embolism was confirmed in 10 (33% of CTPA). The rate of ischemic stroke and ACS/MI was 2.5% and
1.1%, respectively. Overt DIC was present in 8 (2.2%) patients.
Conclusions: The high number of arterial and, in particular, venous thromboembolic events diagnosed within
24 h of admission and the high rate of positive VTE imaging tests among the few COVID-19 patients tested
suggest that there is an urgent need to improve specific VTE diagnostic strategies and investigate the efficacy and
safety of thromboprophylaxis in ambulatory COVID-19 patients.